SPECIAL REPORT

Healthy Horizons
A brand new series of weekly segments which will explore the macro and micro issues facing the global economy.

LATEST FROM OUR BLOGS

» More

- CNBC Video: Warren Buffett & Bill Gates - Keeping American Great

MORE HEADLINES

» Markets | Economy | Companies

- China's Role as Lender Alters Dynamics for United States

PHARMA'S MARKET VIDEO

» More

Novo Nordisk CEO on Diabetes Epidemic

13 Nov 2009

Diabetes is a global epidemic that presents an estimated $25 billion drug and device market and some predict that number could double over the next several years. Lars Sorensen, CEO of Novo Nordisk, the world's largest diabetes care company, talks to CNBC's Mike Huckman.

Pharma & Social Media 12 Nov 2009
The FDA is holding meetings into big pharma's possible use of social media to sell their products. CNBC's Mike Huckman has the details.

"Friending" Big Pharma

12 Nov 2009

Big pharma is embracing social media, but how much can or should a tightly regulated sector be able to say on Facebook or Twitter? CNBC's Mike Huckman takes a closer look.

SNY Out with H1N1 Test Results 11 Nov 2009
Sanofi Aventis confirms that kids 9 and under need not one but two H1N1 shots, with CNBC's Mike Huckman.
Making The Vaccine 06 Nov 2009
Inside the big push to get enough H1N1 vaccines, with CNBC's Mike Huckman.
Making the Flu Vaccine 06 Nov 2009
Wayne Pisano, CEO of Sanofi-Pasteur, discusses the making of the flu vaccine with CNBC's Mike Huckman.

RSS FEED

» Help

Subscribe to this RSS feed
Stay up to date with Pharma's Market.

CNBC ON DIGG

Pharma's Market

Text Size

Sep.04

12:26 PM ET

Thursday, 4 Sep 2008

Amylin's Byetta Battle

Posted By:Mike Huckman

Topics:Pharmaceuticals

Sectors:Health Care Equipment and Services | Health Care | Pharmaceuticals

Companies:Eli Lilly and Company | Amylin Pharmaceuticals

Of the 36 companies presenting here at the BioCentury/Thomson Reuters biotech conference, investors are probably most interested in the update from Amylin Pharmaceuticals.

The stock has been on a slide since the FDA and the company disclosed a total of six deaths among diabetics who developed pancreatitis after taking Byetta, the twice-a-day injectable drug from AMLN[AMLN Loading... () ] and Eli Lilly[LLY Loading... () ].

The CFO Mark Foletta did the presentation to the approximately 100 people in the room. CEO Dan Bradbury didn't make it. Foletta went over the facts that I reported on "Fast Money" when the news broke last week--media coverage that he said has "created some confusion in the marketplace."

"While serious," Foletta said, "it's a condition that is rare and is not new. There's no definitive causal relationship between Byetta and pancreatitis, but a possible association is being explored."

Foletta said he thinks the FDA could change the Byetta label regarding the suspected pancreatitis risk around the time it's expected to make a decision on the approval of Byetta for use as a stand-alone treatment for diabetes. That's supposed to happen, Foletta said, by the end of the year.

He also mentioned--and I think this might be new-- that a "major national insurance carrier" informed the company late last week that among the nearly 40,000 patients it has on Byetta there is "no difference" in the incidence of pancreatitis versus diabetics on other drugs.

One observation, though. Foletta didn't acknowledge the elephant in the room--the pancreatitis-related deaths--until around seven minutes into his formal presentation. In the news biz, that's called burying the lead.